NRx Pharma gains on plans to submit marketing application for depression drug

NRX Pharmaceuticals

20/09/2023 14:37

** Shares of drug developer NRx Pharmaceuticals  NRXP.O  up
4.88% at $0.26
    ** Co says plans to submit marketing application to U.S.
health regulator for NRX-100, its experimental drug for treating
suicidal bipolar depression in 2024
    ** Product treats patients who suffer from acute suicidal
ideational behaviour and bipolar depression
    ** The U.S. Food and Drug Administration has previously 
granted NRX-100 its "fast track" and "breakthrough therapy"
status 
    ** Up to last close, NRXP shares down 77.67%

 (Reporting by Unnamalai L in Bengaluru)
 ((Unnamalai.L@thomsonreuters.com))